PTO/SB/96 (01-09)
Approved for use through 02/28/2009. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)	
Applicant/Patent Owner: CIRC PHARMA RESEARCH AND DEVELOPMENT LIMITED	
Application No./Patent No.: 10/814,293	
Titled: MULTIPARTICULATE BISOPROLOL FORMI	JLATION
CIRC PHARMA RESEARCH AND DEVELOPMEN a Corporation	
(Name of Assignee)	(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.
states that it is:	
1. X the assignee of the entire right, title, and interest	in;
2. an assignee of less than the entire right, title, and interest in (The extent (by percentage) of its ownership interest is%); or	
3. the assignee of an undivided interest in the entirety of (a complete assignment from one of the joint inventors was made)	
the patent application/patent identified above, by virtue of either:	
A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy therefore is attached.	
OR	to the second se
انسنا	application/patent identified above, to the current assignee as follows:
1. From: Atpharma Limited	To: Biovail Laboratories, Inc.
The document was recorded in the Uni Reel 017853, Fram	ited States Patent and Trademark Office at a copy thereof is attached.
2. From: Paul Stark, Catherine Mary Kelly.	Niall M. Fage To: Elan Corporation, PLC
	ited States Patent and Trademark Office at
Reel 022256 Frame	e 0621 or for which a copy thereof is attached.
3. From: Elan Corporation	To: Athpharma Limited
	ited States Patent and Trademark Office at
Reel 022261 , Fram	or for which a copy thereof is attached.
Additional documents in the chain of title are listed on a supplemental sheet(s).	
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.	
(NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]	
The undersigned (whose title is supplied below) is authorized	d to act on behalf of the assignee.
Signature	Date
SEAMUS WULLIGAN	12th March 2009 Date PRESIDENT
Printed or Typed Name	

This coffection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Then will vary depending upon the including ones. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patente, P.O. Box 1450, Alexandria, VA 22313-1450.

## Continuation of Statement Under 37 CFR 3.73(b)

## Application No. 10/814,293 MULTIPARTICULATE BISOPROLOL FORMULATION

4. From: <u>Biovail Holdings LTD/Biovail Laboratories Incorporated</u> To: <u>Biovail Laboratories (2005) Inc.</u>

Reel: <u>017867</u>, Frame: <u>0153</u>

5. From: Biovail Laboratories (2005) Inc. To: Biovail Laboratories International SRL

Reel: 017875 Frame: 0497

6. From: Biovail Laboratories International SRL To: Circ Pharma Research and

**Development Limited** 

Reel: <u>019306</u> Frame: <u>0163</u>